| Document |
Document Title |
|
WO/2018/233509A1 |
Disclosed is an abortion drug. The abortion drug comprises a Phaseolus vulgaris phytohemagglutinin, and the concentration of the Phaseolus vulgaris phytohemagglutinin in the abortion drug is 40-60 mg/ml. The abortion drug may comprise a ...
|
|
WO/2018/235926A1 |
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...
|
|
WO/2018/227829A1 |
A traditional Chinese medicine, comprising bulk materials of: 12 parts of Root of Ligulilobe Sage, 10 parts of Odoriferous Rosewood, 15 parts of Dodder Seed, 10 parts of Himalayan Teasel Root, 10 parts of Chinese Taxillus Herb, 20 parts ...
|
|
WO/2018/231739A1 |
The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.
|
|
WO/2018/224498A1 |
The invention provides methods of treating endometriosis in a patient by administration of a gonadotropin-releasing hormone (GnRH) antagonist, for instance, according to dosing regimens predicated on the patient's level of anti-Mülleria...
|
|
WO/2018/224497A1 |
The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) ...
|
|
WO/2018/226769A1 |
Compounds of Formula (I) that antagonize vasopressin receptors, particularly the Via receptor. The compounds are useful for treating e.g. neuropsychological disorders, such as e.g. anxiety, depression and schizophrenia. Preferred compoun...
|
|
WO/2017/202817A9 |
The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,
3-triazol-4-yl)methanone compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds...
|
|
WO/2018/221521A1 |
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...
|
|
WO/2018/219747A1 |
The present document is directed to a pharmaceutical composition comprising at least one non-ionic cellulose ether, wherein said composition has a viscosity of 35000 cP or more, an osmolality of from about 10 to about 300 mOsmol/kg, and ...
|
|
WO/2018/221966A1 |
The present invention relates to a pharmaceutical composition for prevention or treatment of bone-related diseases, which promotes the differentiation of preosteoblasts into osteoblasts to induce the formation of calcified nodules and si...
|
|
WO/2018/221679A1 |
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.
|
|
WO/2018/220126A1 |
A compound and methods are provided for treating, preventing or ameliorating infertility or reduced fertility in an individual, wherein said compound is capable of regulating the activity of Nuclear Factor, Erythroid 2 Like 2 (NFE2L2).
|
|
WO/2018/216228A1 |
The purpose of the present invention is to establish, as one of bladder regenerative medical techniques, novel treatment which transplants a bone marrow-derived cell structure into a bladder and attempts to regenerate a functional bladde...
|
|
WO/2018/215433A1 |
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-...
|
|
WO/2018/069467A9 |
This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the ...
|
|
WO/2018/214736A1 |
Provided are a polyhydroxyphthalazinone compound, a preparation method therefor and the use thereof, wherein the general formula of the chemical structure of the polyhydroxyphthalazinone compound is as shown by formula (I). The polyhydro...
|
|
WO/2018/211276A1 |
The invention relates to a method of reducing sperm motility or of contraception in a subject, said method comprising the step of administering to said subject an effective amount of a compound of formula (I), a stereoisomer, tautomer, p...
|
|
WO/2018/209809A1 |
The present application relates to a polycrystalline mesylate of a phosphodiesterase type 5 inhibitor. The chemical name of the phosphodiesterase type 5 inhibitor is 5-[2-ethoxy-5-(4-methylpiperazin-1-yl-thiocarbonyl)phenyl]-1
-methyl-3-...
|
|
WO/2018/213125A1 |
Stromal Derived Factor-1 (SDF-1) is a small, naturally occurring, potent chemokine with inherent angiogenic, neurogenic, anti-apoptotic protein, which is also a potent stem cell chemoattractant, cardiovascular disease, and other metaboli...
|
|
WO/2018/212136A1 |
The present invention addresses the problem of providing: an antibody having an internalization activity of binding to CDH6; an antibody-drug conjugate consisting of the aforesaid antibody and a drug having an antitumor activity; a medic...
|
|
WO/2018/212256A1 |
[Problem] To provide a pharmaceutical agent for treatment of pain associated with a gynecological disorder and/or treatment of a structural lesion caused by a gynecological disorder. [Solution] A therapeutic agent for pain associated wit...
|
|
WO/2018/207736A1 |
The present disclosure relates to a method for introducing a polynucleotide to a male germ cell or Sertoli cell, the method including injection of an adeno-associated virus vector containing the polynucleotide to a testicle of a vertebrate.
|
|
WO/2018/206959A1 |
The present invention relates to orexin receptor antagonists, pharmaceutical compositi comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists as m...
|
|
WO/2018/206956A1 |
The present invention relates to orexin receptor antagonists, pharmaceutical compositions comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists a...
|
|
WO/2018/208826A1 |
A method of enhancing sperm fertility is described herein. The method includes contacting sperm with hydroxyurea. A composition is disclosed that includes sperm, hydroxyurea, and a buffer. Methods, kits, and compositions for enhancing sp...
|
|
WO/2018/205191A1 |
An industrial preparation method suitable for extracting four types of quassin ingredient from eurycoma longifolia plants, and an application for preparing products. Ultrasonic countercurrent water extraction and silica gel-low boiling p...
|
|
WO/2018/206923A1 |
The invention relates to multicomponent pharmaceutical compositions which comprise a selective serotonin reuptake inhibitor (SSRI).
|
|
WO/2018/201579A1 |
Medicated chicken, prepared by employing the following ingredients: 500-1000 g of chicken, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equiseti Hiemalis, 3-9 g of...
|
|
WO/2018/201576A1 |
A health-promoting fruit wine, prepared by employing the following ingredients: 400-600 g of grape wine, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equiseti Hiem...
|
|
WO/2018/201578A1 |
Medicated hare or rabbit meat, prepared by employing the following ingredients: 500-1000 g of hare or rabbit meat, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equ...
|
|
WO/2018/201571A1 |
A traditional Chinese medicine composition for treating dysmenorrhea, prepared by employing the following ingredients: 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba...
|
|
WO/2018/201577A1 |
A health-promoting fruit wine, prepared by employing the following ingredients: 400-600 g of grape wine, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equiseti Hiem...
|
|
WO/2018/201570A1 |
A traditional Chinese medicine composition for treating uterine prolapse, prepared by employing the following ingredients: 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of H...
|
|
WO/2018/199748A1 |
The present invention pertains to a calcium binder for use in improving perinatal survival in the offspring of a sow, and in reducing or preventing stillbirth of piglets. The invention also pertains to compositions comprising a calcium b...
|
|
WO/2018/199749A1 |
The present invention pertains to a chloride salt for use in improving colostrum intake in offspring of an animal, in improving colostrum production by an animal, and in improving postnatal survival of offspring of an animal. The inventi...
|
|
WO/2018/199166A1 |
The purpose of the present invention is to provide: compounds having a TrkA inhibiting effect, or pharmacologically acceptable salts thereof, or solvates of these; pharmaceutical compositions characterized by containing these as an activ...
|
|
WO/2018/200977A1 |
A method for treating a impulse control disorder in a patient comprising administering to the patient an effective amount of pimavanserin or a pharmaceutical acceptable salt thereof.
|
|
WO/2018/199291A1 |
The purpose of the present invention is to discover a novel compound having an excellent β-lactamase-inhibiting activity, and to provide a useful prophylactic or therapeutic agent for bacterial infectious diseases which comprises a comb...
|
|
WO/2018/192416A1 |
The invention provides methods of treating male reproductive senescence comprising administering to a male in need thereof a necroptosis inhibitor, including inhibitors of RIP1, RIP3 or MLKL. The invention also provides pharmaceutical co...
|
|
WO/2018/188123A1 |
Disclosed are a microbial adhesion-rate regulator and application thereof, relating to the field of biotechnology. Said microbial adhesion-rate regulator is suitable for regulating the adhesion rate of micro-organisms to a mucous membran...
|
|
WO/2018/191406A1 |
This disclosure relates to improved detection of predictors of preeclampsia.
|
|
WO/2018/184523A1 |
A composition comprising a grape seed extract and a black tea extract. The composition can increase testosterone secretion more effectively than a single component, and can be used for preparing pharmaceutical compositions, foods, health...
|
|
WO/2018/186366A1 |
The present invention addresses the problem of providing a novel cyclin-dependent kinase 8 and/or 19 inhibitor that is useful as an anticancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor that c...
|
|
WO/2018/185321A1 |
A composition or a contraceptive composition comprising a mucoadhesive polymer in a physiologically acceptable carrier, wherein the mucoadhesive polymer consists of 4 to 20monomers units linked to each other via ether, ester or amide bon...
|
|
WO/2018/186480A1 |
The inventors of the present invention found that an HMGB1 peptide fragment having a specific amino acid sequence is effective at suppressing finger fusion and scarring of the digestive tract, and at prolonging survival in malnutrition- ...
|
|
WO/2018/179170A1 |
The present invention addresses the problem of providing a formulation having excellent pharmaceutical effects, in the context of pharmaceutical compositions for treatment of infections (e.g., vaginitis) which contains a compound represe...
|
|
WO/2018/177746A1 |
The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available,...
|
|
WO/2018/170596A1 |
A formulated cannabis product includes a cannabinoid mix and carrier processed by nano-emulsification. The cannabinoid mix in one embodiment includes between 0.1 -0.3% Cannabinol (CBN). This cannabinoid mix is processed into a product yi...
|
|
WO/2018/167689A1 |
Compositions are disclosed herein, as well as methods and uses utilizing the compositions for improving the appearance of aging skin, lightening skin, treating uneven skin pigmentation and/or treating a sexual disorder. The compositions ...
|
